Symptomatic therapies of multiple sclerosis. (Q33770460)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

review article

1 reference

title

Symptomatic therapies of multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

L M Metz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D McGowan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 September 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

Biomedicine and Pharmacotherapy

1 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

371-379

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

The clinical management of spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Long-term intrathecal baclofen therapy in patients with intractable spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Sleep disturbance, depression, and lesion site in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Tetrahydrocannabinol for tremor in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Amantadine treatment of fatigue associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Vim thalamotomy for the relief of the intention tremor of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Gabapentin for relief of spasticity associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Effect of fluoxetine on patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

1 reference

7 January 2021

Recovery of erectile function by the oral administration of apomorphine

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Open label gabapentin treatment for pain in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Sexual function in women with advanced multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Epidural spinal cord stimulation for treatment of chronic pain--some predictors of success. A 15-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Physical and occupational therapy in the treatment of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Chronic neuropathic pain and its control by drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Multiple sclerosis. Sexual dysfunction and its response to medications

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Pain syndromes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Rapid response of emotional incontinence to selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Depression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Recommendations for physical activity in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Effectiveness of gabapentin in controlling spasticity: a quantitative study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Ondansetron for intractable vertigo complicating acute brainstem disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Antidepressant pharmacotherapy of depression associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Treatment of pathologic laughing and weeping with amitriptyline

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Characterization of major depression symptoms in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Fluoxetine improves emotional incontinence

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

The effect of fluoxetine in depression associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Physical rehabilitation has a positive effect on disability in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Valproate in the treatment of mood disorder due to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Sleep problems in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Treatment of trigeminal neuralgia by percutaneous radiofrequency rhizotomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Multiple sclerosis: rehabilitation measures

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980108-5

7 January 2021

10.1016/S0753-3322(99)80108-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10554671%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference